The endocannabinoids system (ECS) has garnered considerable interest as a potential
therapeutic target in various carcinomas and cancer-related conditions alongside …

Psychotic disorders such as schizophrenia are heterogeneous and often debilitating
conditions that contribute substantially to the global burden of disease. The introduction of …

Preclinical and clinical data indicate that cannabidiol (CBD), a non-psychotomimetic
compound from the Cannabis sativa plant, can induce antipsychotic-like effects. In an animal …

The recent shift in socio-political debates and growing liberalization of Cannabis use across
the globe has raised concern regarding its impact on vulnerable populations such as …

Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult
phenotype relevant to schizophrenia, including positive-and negative-like symptoms …

Consumption of cannabinoid-containing products is on the rise, even during pregnancy.
Unfortunately, the long-term, age-related consequences of developmental cannabidiol …

Cannabis consumption during adolescence is an area of particular concern, owing to
changes in the social and political perception of the drug, and presents a scientific, medical …

Cannabidiol (CBD) is a phytocannabinoid contained in the Cannabis sativa plant, devoid of
psychotomimetic effects but with a broad-spectrum pharmacological activity. Because of its …

Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental
disorders that cause high levels of functional disabilities. Also, the currently available …

Objectif: Examiner les données probantes actuelles sur l'efficacité du cannabidiol dans le
traitement des troubles de l'humeur. Méthodes: Nous avons systématiquement recherché …